HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stephen J Gardell Selected Research

1- (2- aminoacetyl)- 4- benzamidopyrrolidine- 2- carboxylic acid

9/2009GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.
6/2009The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stephen J Gardell Research Topics

Disease

3Dyslipidemias (Dyslipidemia)
10/2016 - 03/2009
3Alzheimer Disease (Alzheimer's Disease)
06/2008 - 11/2002
2Weight Loss (Weight Reduction)
01/2021 - 11/2007
2Body Weight (Weight, Body)
01/2018 - 10/2007
2Obesity
12/2013 - 10/2007
2Atherosclerosis
12/2009 - 06/2009
1Overweight
01/2021
1Mitochondrial Diseases (Mitochondrial Disease)
11/2018
1Insulin Resistance
11/2018
1Hyperglycemia
10/2016
1Hypertension (High Blood Pressure)
10/2016
1Heart Failure
02/2016
1Parkinson Disease (Parkinson's Disease)
12/2013
1Cardiovascular Diseases (Cardiovascular Disease)
10/2010
1Cardiac Arrhythmias (Arrythmia)
11/2009
1Ischemia
09/2009
1Reperfusion Injury
09/2009
1Ventricular Tachycardia
09/2009
1Myocardial Ischemia (Ischemic Heart Diseases)
09/2009
1Ventricular Premature Complexes (Premature Ventricular Contraction)
09/2009
1Infarction (Infarctions)
09/2009
1Hypertriglyceridemia
06/2009
1Atrial Fibrillation
06/2009
1Pericarditis
06/2009
1Hypercholesterolemia
03/2009
1Fatty Liver
11/2008
1Weight Gain
11/2007
1Amyloid Plaque
01/2006

Drug/Important Bio-Agent (IBA)

3Proteins (Proteins, Gene)FDA Link
01/2021 - 11/2002
2Biomarkers (Surrogate Marker)IBA
01/2021 - 10/2010
2Fatty Acids (Saturated Fatty Acids)IBA
11/2018 - 02/2016
2Carboxylic AcidsIBA
09/2009 - 06/2009
21- (2- aminoacetyl)- 4- benzamidopyrrolidine- 2- carboxylic acidIBA
09/2009 - 06/2009
2pyrrolidineIBA
09/2009 - 06/2009
2WAY-362450IBA
06/2009 - 03/2009
2Amyloid (Amyloid Fibrils)IBA
06/2008 - 11/2002
2Amyloid beta-PeptidesIBA
06/2008 - 01/2006
2Ghrelin ReceptorsIBA
11/2007 - 10/2007
2Glucose (Dextrose)FDA LinkGeneric
11/2007 - 10/2007
2Peptides (Polypeptides)IBA
01/2006 - 11/2002
1Leucine (L-Leucine)FDA Link
01/2021
1Acetylcarnitine (Alcar)IBA
01/2021
13-Hydroxybutyric Acid (beta-Hydroxybutyric Acid)IBA
01/2021
1Citric Acid (Citrate)FDA LinkGeneric
01/2021
1Isoleucine (L-Isoleucine)FDA Link
01/2021
1Insulin (Novolin)FDA Link
11/2018
1Liver GlycogenIBA
01/2018
1GlycogenIBA
01/2018
1Atenolol (Tenormin)FDA LinkGeneric
10/2016
1Hydroxybutyrate Dehydrogenase (3 Hydroxybutyrate Dehydrogenase)IBA
02/2016
1EnzymesIBA
02/2016
1KetonesIBA
02/2016
1RotenoneIBA
12/2013
1Pharmaceutical PreparationsIBA
10/2010
1LipidsIBA
12/2009
1LDL CholesterolIBA
12/2009
12- (2- chloro- 4- fluorobenzyl)- 3- (4- fluorophenyl)- 7- (trifluoromethyl)- 2H- indazoleIBA
12/2009
1LigandsIBA
12/2009
11- (methylsulfonylamino)- 3- (2- (4- methoxyphenyl)ethyl)- 4- (4- methoxyphenyl)- 2- imidazolidinoneIBA
11/2009
1Polyvinyl Chloride (PVC)IBA
09/2009
1DipeptidesIBA
09/2009
1Bile Acids and Salts (Bile Acids)IBA
06/2009
1HDL CholesterolIBA
06/2009
1Apolipoproteins E (ApoE)IBA
06/2009
1CholesterolIBA
03/2009
1AcidsIBA
11/2008
1IndazolesIBA
11/2008
1SecretagoguesIBA
11/2007
1GhrelinIBA
11/2007
1QuinazolinonesIBA
10/2007
1Amyloid Precursor Protein Secretases (beta-Secretase)IBA
11/2002
1Peptide Hydrolases (Proteases)FDA Link
11/2002

Therapy/Procedure

1Caloric Restriction
01/2021
1Oral Administration
11/2007
1Therapeutics
11/2002